Table 2.
Effect of VISPO Oral Administration on Different Hair Parameters
| VISPO (n=18) | Placebo (n=19) | p-value (VISPO vs Placebo) | |
|---|---|---|---|
| Hair comb test score | |||
| Baseline | 19.56±6.67 | 19.32±7.67 | 0.920‡ |
| Week 8 | 14.72±6.06 | 22.32±7.48 | 0.002‡** |
| Week 16 | 13.89±5.68 | 22.84±6.46 | <0.001‡*** |
| p-value (Baseline vs Week 8) | <0.001#*** | 0.002#** | - |
| p-value (Baseline vs Week 16) | <0.001#*** | 0.030#* | - |
| Hair pull test score | |||
| Baseline | 8.53±0.40 | 8.53±0.31 | 0.990‡ |
| Week 8 | 7.28±0.77 | 8.58±0.38 | <0.001§*** |
| Week 16 | 6.78±0.65 | 8.66±0.37 | <0.001§*** |
| p-value (Baseline vs Week 8) | <0.001†*** | 0.608† | – |
| p-value (Baseline vs Week 16) | <0.001†*** | 0.243† | – |
| Hair density (Hairs/cm2) | |||
| Baseline | 222.56±46.81 | 215.21±29.05 | 0.573‡ |
| Week 8 | 227.56±39.45 | 209.37±30.03 | 0.126‡ |
| Week 16 | 234.06±37.74 | 208.26±29.18 | 0.027‡* |
| p-value (Baseline vs Week 8) | 0.123# | 0.112# | – |
| p-value (Baseline vs Week 16) | 0.009#** | 0.033#* | – |
| Hair thickness (µm) | |||
| Baseline | 16.89±3.46 | 17.16±2.61 | 0.792‡ |
| Week 8 | 17.94±3.90 | 16.89±3.57 | 0.400‡ |
| Week 16 | 19.61±3.26 | 17.53±3.45 | 0.067‡ |
| p-value (Baseline vs Week 8) | 0.249# | 0.759# | - |
| p-value (Baseline vs Week 16) | 0.017#* | 0.636# | - |
| Anagen/Telogen ratio | |||
| Baseline | 3.14±1.01 | 3.19±1.07 | 0.899‡ |
| Week 8 | 3.24±1.32 | 2.94±0.86 | 0.488§ |
| Week 16 | 3.65±1.23 | 2.97±1.20 | 0.112§ |
| p-value (Baseline vs Week 8) | 0.917† | 0.193† | - |
| p-value (Baseline vs Week 16) | 0.139† | 0.533† | - |
Notes: Values are mean±standard deviation (SD). #Paired t-test; ‡Independent t-test; †Wilcoxon signed-rank test; §Mann–Whitney U-test. *p<0.05, **p<0.01 and ***p<0.001.